Antifungal Drugs
 Infectious diseases caused by fungi are called
mycoses, and they are often chronic in nature.
 Fungal infectious occur due to :
 1- Abuse of broad spectrum antibiotics
 2- Decrease in the patient immunity
 They have rigid cell walls composed
largely of a polymer of N-
acetylglucosamine rather than
peptidoglycan (a characteristic component
of most bacterial cell walls).
 The fungal cell membrane contains
ergosterol rather than the cholesterol found
in mammalian membranes.
 These chemical characteristics are useful in
targeting chemotherapeutic agents against
fungal infections
Types of fungal infections
 1. Superficial : Affect skin – mucous
membrane. e.g.
 Tinea versicolor
 Dermatophytes : Fungi that affect
keratin layer of skin, hair, nail. e.g. tinea
pedis ,ring worm infection
 Candidiasis : Yeast-like, oral thrush,
vulvo-vaginitis , nail infections.
2- Deep infections
 Affect internal organs as : lung ,heart ,
brain leading to pneumonia ,
endocarditis , meningitis.
Classification of Antifungal Drugs
1- Antifungal Antibiotics :
 Griseofulvin
 Polyene macrolide : Amphotericin- B &
Nystatin
2- Synthetic :
 Azoles :
A) Imidazoles : Ketoconazole , Miconazole
B) Triazoles : Fluconazole , Itraconazole
Synthetic Antifungal ( contin…)
 Flucytosine
 Squalene epoxidase inhibitors :
e.g.Terbinafine & Naftifine.
Classification According to Route of
Administration
 Systemic :
Griseofulvin , Amphotericin- B , Ketoconazole ,
Fluconazole , Terbinafine.
 Topical
In candidiasis :
 Imidazoles : Ketoconazole , Miconazole.
 Triazoles : Terconazole.
 Polyene macrolides : Nystatin , Amphotericin-B
 Gentian violet : Has antifungal & antibacterial.
In Dermatophytes :
 Squalene epoxidase inhibitors : Terbinafine &
Naftifine.
 Tolnaftate.
 White field ointment : 11% Benzoic acid &
6% Salicylic acid .
 Castellani paint.
Amphotericin B
 Amphotericin A & B are antifungal
antibiotics.
 Amphotericin A is not used clinically.
 It is a natural polyene macrolide
 (polyene = many double bonds )
 (macrolide = containing a large lactone ring )
Pharmacokinetics
 Poorly absorbed orally , is effective for fungal
infection of gastrointestinal tract.
 For systemic infections given as slow I.V.I.
 Highly bound to plasma protein .
 Poorly crossing BBB.
 Metabolized in liver
 Excreted slowly in urine over a period of
several days.
 Half-life 16 days.
Mechanism of action
 It is a selective fungicidal drug.
 Disrupt fungal cell membrane by binding to
ergosterol , so alters the permeability of the
cell membrane leading to leakage of
intracellular ions & macromolecules (cell
death ).
Resistance to amphotericin B
If ergosterol binding is impaired either by :
 Decreasing the membrane concentration of
ergosterol.
 Or by modifying the sterol target molecule.
Adverse Effects
1- Immediate reactions (Infusion –related toxicity).
 Fever, muscle spasm, vomiting, headache, hypotension.
Can be avoided by:
A. Slowing the infusion
B. Decreasing the daily dose
C.Premedication with antipyretics, antihistamincs or
corticosteroids.
D. A test dose.
2- Slower toxicity
 Most serious is renal toxicity (nearly in all
patients ).
 Hypokalemia
 Hypomagnesaemia
 Impaired liver functions
 Thrombocytopenia
 Anemia
Clinical uses
 Has a broad spectrum of activity & fungicidal action.
 The drug of choice for life-threatening mycotic
infections.
 For induction regimen for serious fungal infection.
 Also, for chronic therapy & preventive therapy of
relapse.
 In cancer patients with neutropenia who remain
febrile on broad –spectrum antibiotics.
Routes of Administration
1- Slow I.V.I. For systemic fungal disease.
2- Intrathecal for fungal C.N.S. infections.
3- Topical drops & direct subconjunctival
injection for Mycotic corneal ulcers & keratitis.
3- Local injection into the joint in fungal arthritis.
4- Bladder irrigation in Candiduria.
Liposomal preparations of
amphotericin B
 Amphotericin B is packaged in a lipid-
associated delivery system to reduce binding to
human cell membrane , so reducing :
A. Nephrotoxicity
B. Infusion toxicity
 Also, more effective
 More expensive
Nystatin
 It is a polyene macrolide ,similar in structure
& mechanism to amphotericin B.
 Too toxic for systemic use.
 Used only topically.
 It is available as creams, ointment ,
suppositories & other preparations.
 Not significantly absorbed from skin, mucous
membrane, GIT .
Clinical uses
 Prevent or treat superficial candidiasis of
mouth, esophagus, intestinal tract.
 Vaginal candidiasis
 Can be used in combination with antibacterial
agents & corticosteroids.
Azoles
 A group of synthetic fungistatic agents with a
broad spectrum of activity .
 They have antibacterial , antiprotozoal
anthelminthic & antifungal activity .
Mechanism of Action
1-Inhibit the fungal cytochrome P450 enzyme, (α-
demethylase) which is responsible for converting
lanosterol to ergosterol ( the main sterol in fungal
cell membrane ).
2- Inhibition of mitochondrial cytochrome
oxidase leading to accumulation of peroxides that
cause autodigestion of the fungus.
3- Imidazoles may alter RNA& DNA metabolism.
Azoles
They are classified into :
 Imidazole group
 Triazole group
Imidazoles
 Ketoconazole
 Miconazole
 Clotrimazole
 They lack selectivity ,they inhibit human
gonadal and steroid synthesis leading to
decrease testosterone & cortisol production.
 Also, inhibit human P-450 hepatic enzyme.
Ketoconazole
 Well absorbed orally .
 Bioavailability is decreased with antacids, H2
blockers , proton pump inhibitors & food .
 Cola drinks improve absorption in patients
with achlorhydria.
 Half-life increases with the dose , it is (7-8 hrs).
Ketoconazole (cont.)
 Inactivated in liver & excreted in bile (feces )
& urine.
 Does not cross BBB.
Clinical uses
 Used topically or systematic (oral route only )
to treat :
1- Oral & vaginal candidiasis.
2- Dermatophytosis.
3- Systemic mycoses.
Adverse Effects
 Nausea, vomiting ,anorexia
 Hepatotoxic
 Inhibits human P 450 enzymes
 Inhibits adrenal & gonadal steroids leading to:
Menstrual irregularities
Loss of libido
Impotence
Gynaecomastia in males
Contraindications & Drug interactions
Contraindicated in :
 Prgnancy, lactation ,hepatic dysfunction
 Interact with enzyme inhibitors , enzyme
inducers.
 H2 blockers & antacids decrease its absorption
Triazoles
 Fluconazole
 Itraconazole
 Voriconazole
 They are :
 Selective
 Resistant to degradation
 Causing less endocrine disturbance
Itraconazole
 Lacks endocrine side effects
 Has a broad spectrum activity
 Given orally & IV
 Food increases its absorption
 Metabolized in liver to active metabolite
 Highly lipid soluble ,well distributed to bone,
sputum ,adipose tissues.
 Can not cross BBB
Itraconazole (cont.)
 Half-life 30-40 hours
 Used orally in dermatophytosis & vulvo-
vaginal candidiasis.
 IV only in serious infections.
 Effective in AIDS-associated histoplasmosis
 Side effects :
 Nausea, vomiting, hypokalemia, hypertension,
edema, inhibits the metabolism of many drugs
as oral anticoagulants.
Fluconazole
 Water soluble
 Completely absorbed from GIT
 Excellent bioavailability after oral
administration
 Bioavailability is not affected by food or
gastric PH
 Concentrated in plasma is same by oral or IV
route
 Has the least effect on hepatic microsomal
enzymes
Fluconazole (cont.)
 Drug interactions are less common
 Penetrates well BBB so, it is the drug of choice
of cryptococcal meningitis
 Safely given in patients receiving bone marrow
transplants (reducing fungal infections)
 Excreted mainly through kidney
 Half-life 25-30 hours
 Resistance is not a problem
Clinical uses
 Candidiasis
 ( is effective in all forms of mucocutaneous
candidiasis)
 Cryptococcus meningitis
 Histoplasmosis, blastomycosis, , ring worm.
 Not effective in aspergillosis
Side effects
 Nausea, vomiting, headache, skin rash ,
diarrhea, abdominal pain , reversible alopecia.
 Hepatic failure may lead to death
 Highly teratogenic ( as other azoles)
 Inhibit P450 cytochrome
 No endocrine side effects
Voriconazole
 A broad spectrum antifungal agent
 Given orally or IV
 High oral bioavailability
 Penetrates tissues well including CSF
 Inhibit P450
 Used for the treatment of invasive aspergillosis
& serious infections.
 Reversible visual disturbances
Flucytosine
 Synthetic pyrimidine antimetabolite (cytotoxic
drug ) often given in combination with
amphotericin B & itraconazole.
 Systemic fungistatic
Mechanism of action
 Converted within the fungal cell to 5-
fluorouracil (Not in human cell ), that inhibits
thymidylate synthetase enzyme that inhibits
DNA synthesis.
 (Amphotericin B increases cell permeability ,
allowing more 5-FC to penetrate the cell, they
are synergistic).
Phrmacokinetics
 Rapidly & well absorbed orally
 Widely distributed including CSF.
 Mainly excreted unchanged through kidney
 Half-life 3-6 hours
Clinical uses
 Severe deep fungal infections as in meningitis
 Generally given with amphotericin B
 For cryptococcal meningitis in AIDS patients
Adverse Effects
 Nausea, vomiting , diarrhea, severe
enterocolitis
 Reversible neutropenia, thrombocytopenia,
bone marrow depression
 Alopecia
 Elevation in hepatic enzymes
Caspofungin
 Inhibits the synthesis of fungal cell wall by
inhibiting the synthesis of β(1,3)-D-glucan,
leading to lysis & cell death.
 Given by IV route only
 Highly bound to plasma proteins
 Half-life 9-11 hours
 Slowly metabolized by hydrolysis & N-
acetylation.
 Elimination is nearly equal between the
urinary & fecal routes.
Clinical uses
 Effective in aspergillus & candida infections.
 Second line for those who have failed or
cannot tolerate amphotericin B or
itraconazole.
 Adverse effects :
 Nausea, vomiting
 Flushing (release of histamine from mast cells)
 Very expensive
Griseofulvin
 Fungistatic, has a narrow spectrum
 Given orally (Absorption increases with fatty
meal )
 Half-life 26 hours
 Taken selectively by newly formed skin &
concentrated in the keratin.
 Induces cytochrome P450 enzymes
 Should be given for 2-6weeks for skin & hair
infections to allow replacement of infected
keratin by the resistant structure
Griseofulvin(cont.)
 Inhibits fungal mitosis by interfering with microtubule
function
 Used to treat dermatophyte infections ( ring worm of
skin, hair, nails ).
 Highly effective in athlete,s foot.
 Ineffective topically.
 Not effective in subcutaneous or deep mycosis.
 Adverse effects ;
 Peripheral neuritis, mental confusion, fatigue, vertigo,
GIT upset, enzyme inducer, blurred vision.
 Increases alcohol intoxication.
TOLNAFTATE
 Effective in most cutaneous mycosis.
 Ineffective against Candida.
 Used in tinea pedis ( cure rate 80% ).
 Used as cream, gel, powder, topical solution.
 Applied twice daily.
NAFTIFINE
 Broad spectrum fungicidal .
 Available as cream or gel.
 Effective for treatment of tinea cruris.
TERBINAFINE
 Drug of choice for treating dermatophytes
(onychomycoses).
 Better tolerated ,needs shorter duration of
therapy.
 Inhibits fungal squalene epoxidase, decreases
 The synthesis of ergosterol .(Accumulation of
squalene ,which is toxic to the organism
causing death of fungal cell).
 Fungicidal ,its activity is limited to candida
albicans & dermatophytes.
 Effective for treatment of onychomycoses
 6 weeks for finger nail infection & 12 weeks
for toe nail infections .
 Well absorbed orally , bioavailability
decreases due to first pass metabolism in liver.
 Highly protein binding
 Accumulates in skin , nails, fat.
 Severely hepatotoxic, liver failure even death.
 Accumulate in breast milk , should not be
given to nursing mother.
 GIT upset (diarrhea, dyspepsia, nausea )
 Taste & visual disturbance.
Antifungal drugs

Antifungal drugs

  • 1.
    Antifungal Drugs  Infectiousdiseases caused by fungi are called mycoses, and they are often chronic in nature.  Fungal infectious occur due to :  1- Abuse of broad spectrum antibiotics  2- Decrease in the patient immunity
  • 2.
     They haverigid cell walls composed largely of a polymer of N- acetylglucosamine rather than peptidoglycan (a characteristic component of most bacterial cell walls).  The fungal cell membrane contains ergosterol rather than the cholesterol found in mammalian membranes.  These chemical characteristics are useful in targeting chemotherapeutic agents against fungal infections
  • 3.
    Types of fungalinfections  1. Superficial : Affect skin – mucous membrane. e.g.  Tinea versicolor  Dermatophytes : Fungi that affect keratin layer of skin, hair, nail. e.g. tinea pedis ,ring worm infection  Candidiasis : Yeast-like, oral thrush, vulvo-vaginitis , nail infections.
  • 4.
    2- Deep infections Affect internal organs as : lung ,heart , brain leading to pneumonia , endocarditis , meningitis.
  • 5.
    Classification of AntifungalDrugs 1- Antifungal Antibiotics :  Griseofulvin  Polyene macrolide : Amphotericin- B & Nystatin 2- Synthetic :  Azoles : A) Imidazoles : Ketoconazole , Miconazole B) Triazoles : Fluconazole , Itraconazole
  • 6.
    Synthetic Antifungal (contin…)  Flucytosine  Squalene epoxidase inhibitors : e.g.Terbinafine & Naftifine.
  • 7.
    Classification According toRoute of Administration  Systemic : Griseofulvin , Amphotericin- B , Ketoconazole , Fluconazole , Terbinafine.  Topical In candidiasis :  Imidazoles : Ketoconazole , Miconazole.  Triazoles : Terconazole.  Polyene macrolides : Nystatin , Amphotericin-B  Gentian violet : Has antifungal & antibacterial.
  • 8.
    In Dermatophytes : Squalene epoxidase inhibitors : Terbinafine & Naftifine.  Tolnaftate.  White field ointment : 11% Benzoic acid & 6% Salicylic acid .  Castellani paint.
  • 9.
    Amphotericin B  AmphotericinA & B are antifungal antibiotics.  Amphotericin A is not used clinically.  It is a natural polyene macrolide  (polyene = many double bonds )  (macrolide = containing a large lactone ring )
  • 10.
    Pharmacokinetics  Poorly absorbedorally , is effective for fungal infection of gastrointestinal tract.  For systemic infections given as slow I.V.I.  Highly bound to plasma protein .  Poorly crossing BBB.  Metabolized in liver  Excreted slowly in urine over a period of several days.  Half-life 16 days.
  • 11.
    Mechanism of action It is a selective fungicidal drug.  Disrupt fungal cell membrane by binding to ergosterol , so alters the permeability of the cell membrane leading to leakage of intracellular ions & macromolecules (cell death ).
  • 13.
    Resistance to amphotericinB If ergosterol binding is impaired either by :  Decreasing the membrane concentration of ergosterol.  Or by modifying the sterol target molecule.
  • 14.
    Adverse Effects 1- Immediatereactions (Infusion –related toxicity).  Fever, muscle spasm, vomiting, headache, hypotension. Can be avoided by: A. Slowing the infusion B. Decreasing the daily dose C.Premedication with antipyretics, antihistamincs or corticosteroids. D. A test dose.
  • 15.
    2- Slower toxicity Most serious is renal toxicity (nearly in all patients ).  Hypokalemia  Hypomagnesaemia  Impaired liver functions  Thrombocytopenia  Anemia
  • 16.
    Clinical uses  Hasa broad spectrum of activity & fungicidal action.  The drug of choice for life-threatening mycotic infections.  For induction regimen for serious fungal infection.  Also, for chronic therapy & preventive therapy of relapse.  In cancer patients with neutropenia who remain febrile on broad –spectrum antibiotics.
  • 17.
    Routes of Administration 1-Slow I.V.I. For systemic fungal disease. 2- Intrathecal for fungal C.N.S. infections. 3- Topical drops & direct subconjunctival injection for Mycotic corneal ulcers & keratitis. 3- Local injection into the joint in fungal arthritis. 4- Bladder irrigation in Candiduria.
  • 18.
    Liposomal preparations of amphotericinB  Amphotericin B is packaged in a lipid- associated delivery system to reduce binding to human cell membrane , so reducing : A. Nephrotoxicity B. Infusion toxicity  Also, more effective  More expensive
  • 20.
    Nystatin  It isa polyene macrolide ,similar in structure & mechanism to amphotericin B.  Too toxic for systemic use.  Used only topically.  It is available as creams, ointment , suppositories & other preparations.  Not significantly absorbed from skin, mucous membrane, GIT .
  • 21.
    Clinical uses  Preventor treat superficial candidiasis of mouth, esophagus, intestinal tract.  Vaginal candidiasis  Can be used in combination with antibacterial agents & corticosteroids.
  • 22.
    Azoles  A groupof synthetic fungistatic agents with a broad spectrum of activity .  They have antibacterial , antiprotozoal anthelminthic & antifungal activity .
  • 23.
    Mechanism of Action 1-Inhibitthe fungal cytochrome P450 enzyme, (α- demethylase) which is responsible for converting lanosterol to ergosterol ( the main sterol in fungal cell membrane ). 2- Inhibition of mitochondrial cytochrome oxidase leading to accumulation of peroxides that cause autodigestion of the fungus. 3- Imidazoles may alter RNA& DNA metabolism.
  • 24.
    Azoles They are classifiedinto :  Imidazole group  Triazole group
  • 25.
    Imidazoles  Ketoconazole  Miconazole Clotrimazole  They lack selectivity ,they inhibit human gonadal and steroid synthesis leading to decrease testosterone & cortisol production.  Also, inhibit human P-450 hepatic enzyme.
  • 26.
    Ketoconazole  Well absorbedorally .  Bioavailability is decreased with antacids, H2 blockers , proton pump inhibitors & food .  Cola drinks improve absorption in patients with achlorhydria.  Half-life increases with the dose , it is (7-8 hrs).
  • 27.
    Ketoconazole (cont.)  Inactivatedin liver & excreted in bile (feces ) & urine.  Does not cross BBB.
  • 28.
    Clinical uses  Usedtopically or systematic (oral route only ) to treat : 1- Oral & vaginal candidiasis. 2- Dermatophytosis. 3- Systemic mycoses.
  • 29.
    Adverse Effects  Nausea,vomiting ,anorexia  Hepatotoxic  Inhibits human P 450 enzymes  Inhibits adrenal & gonadal steroids leading to: Menstrual irregularities Loss of libido Impotence Gynaecomastia in males
  • 30.
    Contraindications & Druginteractions Contraindicated in :  Prgnancy, lactation ,hepatic dysfunction  Interact with enzyme inhibitors , enzyme inducers.  H2 blockers & antacids decrease its absorption
  • 32.
    Triazoles  Fluconazole  Itraconazole Voriconazole  They are :  Selective  Resistant to degradation  Causing less endocrine disturbance
  • 33.
    Itraconazole  Lacks endocrineside effects  Has a broad spectrum activity  Given orally & IV  Food increases its absorption  Metabolized in liver to active metabolite  Highly lipid soluble ,well distributed to bone, sputum ,adipose tissues.  Can not cross BBB
  • 34.
    Itraconazole (cont.)  Half-life30-40 hours  Used orally in dermatophytosis & vulvo- vaginal candidiasis.  IV only in serious infections.  Effective in AIDS-associated histoplasmosis  Side effects :  Nausea, vomiting, hypokalemia, hypertension, edema, inhibits the metabolism of many drugs as oral anticoagulants.
  • 35.
    Fluconazole  Water soluble Completely absorbed from GIT  Excellent bioavailability after oral administration  Bioavailability is not affected by food or gastric PH  Concentrated in plasma is same by oral or IV route  Has the least effect on hepatic microsomal enzymes
  • 36.
    Fluconazole (cont.)  Druginteractions are less common  Penetrates well BBB so, it is the drug of choice of cryptococcal meningitis  Safely given in patients receiving bone marrow transplants (reducing fungal infections)  Excreted mainly through kidney  Half-life 25-30 hours  Resistance is not a problem
  • 37.
    Clinical uses  Candidiasis ( is effective in all forms of mucocutaneous candidiasis)  Cryptococcus meningitis  Histoplasmosis, blastomycosis, , ring worm.  Not effective in aspergillosis
  • 38.
    Side effects  Nausea,vomiting, headache, skin rash , diarrhea, abdominal pain , reversible alopecia.  Hepatic failure may lead to death  Highly teratogenic ( as other azoles)  Inhibit P450 cytochrome  No endocrine side effects
  • 39.
    Voriconazole  A broadspectrum antifungal agent  Given orally or IV  High oral bioavailability  Penetrates tissues well including CSF  Inhibit P450  Used for the treatment of invasive aspergillosis & serious infections.  Reversible visual disturbances
  • 40.
    Flucytosine  Synthetic pyrimidineantimetabolite (cytotoxic drug ) often given in combination with amphotericin B & itraconazole.  Systemic fungistatic
  • 41.
    Mechanism of action Converted within the fungal cell to 5- fluorouracil (Not in human cell ), that inhibits thymidylate synthetase enzyme that inhibits DNA synthesis.  (Amphotericin B increases cell permeability , allowing more 5-FC to penetrate the cell, they are synergistic).
  • 42.
    Phrmacokinetics  Rapidly &well absorbed orally  Widely distributed including CSF.  Mainly excreted unchanged through kidney  Half-life 3-6 hours
  • 43.
    Clinical uses  Severedeep fungal infections as in meningitis  Generally given with amphotericin B  For cryptococcal meningitis in AIDS patients
  • 44.
    Adverse Effects  Nausea,vomiting , diarrhea, severe enterocolitis  Reversible neutropenia, thrombocytopenia, bone marrow depression  Alopecia  Elevation in hepatic enzymes
  • 45.
    Caspofungin  Inhibits thesynthesis of fungal cell wall by inhibiting the synthesis of β(1,3)-D-glucan, leading to lysis & cell death.  Given by IV route only  Highly bound to plasma proteins  Half-life 9-11 hours  Slowly metabolized by hydrolysis & N- acetylation.  Elimination is nearly equal between the urinary & fecal routes.
  • 46.
    Clinical uses  Effectivein aspergillus & candida infections.  Second line for those who have failed or cannot tolerate amphotericin B or itraconazole.  Adverse effects :  Nausea, vomiting  Flushing (release of histamine from mast cells)  Very expensive
  • 47.
    Griseofulvin  Fungistatic, hasa narrow spectrum  Given orally (Absorption increases with fatty meal )  Half-life 26 hours  Taken selectively by newly formed skin & concentrated in the keratin.  Induces cytochrome P450 enzymes  Should be given for 2-6weeks for skin & hair infections to allow replacement of infected keratin by the resistant structure
  • 48.
    Griseofulvin(cont.)  Inhibits fungalmitosis by interfering with microtubule function  Used to treat dermatophyte infections ( ring worm of skin, hair, nails ).  Highly effective in athlete,s foot.  Ineffective topically.  Not effective in subcutaneous or deep mycosis.  Adverse effects ;  Peripheral neuritis, mental confusion, fatigue, vertigo, GIT upset, enzyme inducer, blurred vision.  Increases alcohol intoxication.
  • 49.
    TOLNAFTATE  Effective inmost cutaneous mycosis.  Ineffective against Candida.  Used in tinea pedis ( cure rate 80% ).  Used as cream, gel, powder, topical solution.  Applied twice daily.
  • 50.
    NAFTIFINE  Broad spectrumfungicidal .  Available as cream or gel.  Effective for treatment of tinea cruris.
  • 51.
    TERBINAFINE  Drug ofchoice for treating dermatophytes (onychomycoses).  Better tolerated ,needs shorter duration of therapy.  Inhibits fungal squalene epoxidase, decreases  The synthesis of ergosterol .(Accumulation of squalene ,which is toxic to the organism causing death of fungal cell).
  • 52.
     Fungicidal ,itsactivity is limited to candida albicans & dermatophytes.  Effective for treatment of onychomycoses  6 weeks for finger nail infection & 12 weeks for toe nail infections .  Well absorbed orally , bioavailability decreases due to first pass metabolism in liver.
  • 53.
     Highly proteinbinding  Accumulates in skin , nails, fat.  Severely hepatotoxic, liver failure even death.  Accumulate in breast milk , should not be given to nursing mother.  GIT upset (diarrhea, dyspepsia, nausea )  Taste & visual disturbance.